Larimar Therapeutics Inc
(LRMR)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 111,524 | 26,825 | 86,047 | 19,736 | 62,564 |
| Marketable Securities | 0 | 91,603 | 38,652 | 35,188 | N/A |
| TOTAL | $113,464 | $120,739 | $127,127 | $56,744 | $64,879 |
| Non-Current Assets | |||||
| PPE Net | 753 | 831 | 909 | 986 | 1,067 |
| Other Non-Current Assets | 4,690 | 4,835 | 4,979 | 5,122 | 5,277 |
| TOTAL | $5,443 | $5,666 | $5,888 | $6,108 | $6,344 |
| Total Assets | $118,907 | $126,405 | $133,015 | $62,852 | $71,223 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 695 | 1,686 | 849 | 425 | 2,417 |
| Accrued Expenses | 6,726 | 8,408 | 7,939 | 6,656 | 5,840 |
| TOTAL | $8,010 | $10,705 | $9,420 | $7,719 | $8,873 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 4,656 | 4,797 | 4,933 | 5,077 | 5,245 |
| TOTAL | $4,656 | $4,797 | $4,933 | $5,077 | $5,245 |
| Total Liabilities | $12,666 | $15,502 | $14,353 | $12,796 | $14,118 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 43,269 | 43,269 | 43,269 | 17,710 | 17,710 |
| Common Shares | 43 | 43 | 43 | 18 | 18 |
| Retained earnings | -158,131 | -151,605 | -142,180 | -133,860 | -125,193 |
| Other shareholders' equity | 0 | -31 | -40 | -57 | 0 |
| TOTAL | $106,241 | $110,903 | $118,662 | $50,056 | $57,105 |
| Total Liabilities And Equity | $118,907 | $126,405 | $133,015 | $62,852 | $71,223 |